Physician profile
Jason Roy
NPI 1558321133
$94,733.25
in general payments reported to CMS, 2019-2025
46 companies · $38K in 2025
The $38K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,631 · 2022: $2,357 · 2023: $23K · 2024: $27K · 2025: $38K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $50K · Food and Beverage: $17K · Consulting Fee: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,075 · Travel and Lodging: $3,093 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $50,000.00 |
| Food and Beverage | $17,024.23 |
| Consulting Fee | $11,441.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,075.00 |
| Travel and Lodging | $3,092.99 |
| Education | $111.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intra-Sana Laboratories | $54,263.48 | 2021-2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Madrigal Pharmaceuticals | $12,502.37 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $5,620.27 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $4,904.23 | 2021-2025 | |
| Abbvie INC. | $4,106.87 | 2021-2025 | |
| Pfizer INC. | $1,719.22 | 2021-2025 | |
| Janssen Biotech, INC. | $1,464.51 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Fresenius Kabi USA, LLC | $1,358.05 | 2023-2024 | Idacio |
| Takeda Pharmaceuticals U.S.A., INC. | $1,183.71 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Scientific Affairs, LLC | $943.77 | 2021-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $702.08 | 2023-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $612.43 | 2021-2025 | Ocaliva |
| Ardelyx, INC. | $520.80 | 2023-2025 | Ibsrela |
| Celltrion USA INC. | $399.38 | 2024-2025 | Zymfentra, Vegzelma |
| Braintree Laboratories, INC. | $394.24 | 2021-2025 | Sutab, Suflave |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.